MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia

TLDR MiNK Therapeutics stock moves after Phase 2 pneumonia trial update. agenT-797 shows early gains in oxygenation and infection control. Data presented at 2026 Military Health System Research Symposium event. Patients treated in Ukraine show no major adverse events reported. MiNK Therapeutics advances off-the-shelf iNKT therapy for lung injury. INKT shares traded at $11.48 after [...]

The post MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia appeared first on Blockonomi.